Nox Health Closes Acquisition of Somryst
Nox Health has closed the acquisition of Somryst, the only FDA-approved prescription digital therapeutic for adults with chronic insomnia, from Pear Therapeutics.
Tag: Pear Therapeutics
All
Latest
All
Latest
Somryst Lowers Insomnia, Anxiety Symptoms, Depression Severity Through Six Months
Insomnia is linked with anxiety and depression, and a clinical trial evaluates the impact of Somryst on these comorbidities.
All
Latest
Why Holistic Treatments for Insomnia Are Becoming More Popular
Though many people with insomnia go into doctor’s visits expecting a drug to relieve sleeplessness, stakeholders are moving increasingly toward holistic approaches.
Digital Cognitive Behavioral Therapy for Insomnia Comparison Guide
Compare distribution platforms, data transmittal, available physician reports, payment options, FDA status, internet requirements, and supporting studies for digital CBT-I options.
Read MoreDigital CBT-I Maker Completes Series D Financing & Plans to Use It to Accelerate Reimbursement Coverage
Pear will use the financing to accelerate reimbursement coverage for its products, creating a market access pathway in the prescription digital therapeutics industry.
Read More
Somryst Prescription Digital CBT-I Now Available to Insomnia Patients
Pear Therapeutics’s Somryst, a prescription digital therapeutic for use in the treatment of patients with chronic insomnia, is now available for patient use.
Read More
Pear Therapeutics Wins Prix Galien USA Award for Somryst as Best Digital Health Product
The award recognizes the cognitive behavioral therapy for insomnia software for impacting patient care through innovation.
Read MoreTwo Studies Evaluating Digital Therapeutic for Chronic Insomnia Presented at Virtual SLEEP 2020
The digital nature of Somryst offers opportunities to probe the user experience at a granular level.
Read MoreFDA OKed Insomnia Digital Therapy Begins Enrolling Participants for Real-World Impact Trial
Pear has developed its own decentralized and fully virtual clinical trial infrastructure for participant recruitment, screening, consent, enrollment, follow up, and progress tracking, which will be used for the DREAM study.
Read More
Insomnia Prescription Digital Therapeutic Leads the Way in FDA’s Software Precertification Pilot Program
The FDA has granted authorization for Somryst, the first prescription digital therapeutic intended for use in the treatment of patients with chronic insomnia.
Read More